Streetwise Biotech / Pharmaceuticals Articles



Pharma Co. May Have Accelerated FDA Approval in 2024
Source: Edward White  (12/20/23)
TRACON Pharmaceuticals Inc. provided an update on enrollment progress for their ongoing Phase 2 ENVASARC clinical trial testing the drug envafolimab to treat sarcoma, reported H.C. Wainwright & Co. More >


Bioscience Co. Expands Collaboration
Source: Dr. Jonathan Aschoff  (12/19/23)
This bioscience company's price target implies 680% upside, according to a Roth MKM report. More >


Ron Struthers

Promising Biotech Selling Way Under Cash Value
Source: Ron Struthers  (12/18/23)
Nkarta is using CRISPR technology for cell therapies for leukemia. The FDA just approved a similar cell therapy treatment for Vertex using the same CRISPR technology. Nkarta is trading well below cash value and has a significant short position sinking underwater. More >


Texas Biotech Advances Lead Candidate in Resistant AML
Source: Dr. Jonathan Aschoff  (12/14/23)
Recently, Texas-based biotech Bio-Path Holdings Inc. announced it had completed the first safety cohort of a Phase 1/1b trial evaluating the developmental drug BP1002 in acute myeloid leukemia (AML). Read on to see what one Roth analyst has to say about the company's stock. More >


Biotech Seeks Approval of Synthetic Blood Vessel Graft
Source: Vernon Bernardino  (12/12/23)
Humacyte Inc. announced the submission of a Biologics License Application (BLA) to the FDA seeking approval for its lead product candidate Human Acellular Vessel (HAV), noted H.C. Wainwright & Co. Analyst Vernon Bernardino. More >


Drugs Show Anti-Cancer Effects on Myeloma Cells
Source: Dr. Jonathan Aschoff  (12/6/23)
These positive results bode well for the biopharma's two polyamine inhibitors as potential treatments for multiple myeloma, noted a ROTH Capital Markets report. More >


Antibodies from Vaccine Remain Two Years Out
Source: Edward White  (12/6/23)
This was shown in recent clinical trial results of a biotech's single-dose vaccine against chikungunya evaluated in adults, noted an H.C. Wainwright & Co. report. More >


Pharma Co. Reports Positive Data for Leukemia Combination Therapy
Source: Andrew Fein  (12/6/23)
Recently, Syros Pharmaceuticals Inc. announced positive data for its Leukemia Combination Therapy, noted an H.C. Wainwright & Co. report. More >


Massachusetts Biotech Plummets as Skin Cancer Trial Fails
Source: Streetwise Reports  (12/5/23)
In recent news, Massachusetts clinical-stage biotechnology company Replimune Group Inc. revealed its latest clinical trial did not meet the endpoints needed to call it a success. With this, the stock has plummeted. More >


Pharma Co.'s Partnership a Key Validation
Source: Dr. Robert Driscoll  (12/4/23)
Recently, Arcus Biosciences Inc. announced a partnership with Exelixis Inc., which may be the key to validating the company, noted WedBush analysts in a December 4 report. More >


Biotech Announces New Responder in Breast Cancer Trail
Source: Emily Bodnar  (11/30/23)
Recently, BriaCell Therapeutics Corp. announced a new exceptional responder in its Phase 2 study evaluating the company's off-the-shelf personalized immunotherapy, noted H.C. Wainwright analyst Emily Bodnar. More >


Biotech Receives First Approval; Drug Now Available
Source: Robert Burns  (11/28/23)
Recently, SpringWorks Therapeutics Inc. announced FDA approval of OGSIVEO (nirogacestat) for treating progressing desmoid tumors (DT) in adult patients based on Phase 3 DeFi trial results, noted H.C. Wainwright & Co. analysts Robert Burns and Dr. Raghuram Selvaraju. More >


Encouraging Early Data For Biotech's Cancer Therapies
Source: Emily Bodnar  (11/21/23)
In a recent corporate update, Purple Biotech Ltd. reported positive interim Phase 1/2 data for NT219 and accelerated enrollment for CM24, noted H.C. Wainwright analyst Emily Bodnar. More >


Strong Early Launch Metrics for Biotech's Skin Disease Drug
Source: Oren Livnat  (11/20/23)
Oren Livnat of H.C. Wainwright & Co. sees over 240% upside potential for Verrica Pharmaceuticals based on the early commercial success of its recently launched skin disease treatment. More >


Arizona Biotech Advances Multiple Cell Therapies
Source: Dr. Jonathan Aschoff  (11/16/23)
Roth MKM has a US$30 price target on this biotech company based on progress across its regenerative medicine pipeline, including upcoming Phase 1/2 data. More >


Massachusetts Biotech Advances Novel Cytokine Therapies
Source: Dr. Robert Driscoll  (11/15/23)
Wedbush sees over 300% upside for Werewolf stock based on early clinical success for its PREDATOR platform and pipeline, according to a WedBush research note. More >


Massachusetts Biotech Presents Catalysts Into 2024
Source: Dr. David Nierengarten  (11/8/23)
Cambridge, Massachusetts-based iTeos Therapeutics presented multiple upcoming catalysts into 2024 after reporting Q3 results, noted Wedbush analyst Dr. David Nierengarten. More >


Texas Biotech Exceeds Alzheimer's Trial Enrollment Target
Source: Vernon Bernardino  (11/8/23)
This Texas-based biotech company's enrollment in its two pivotal Phase 3 trials evaluating lead drug candidate simufilam for Alzheimer's disease surpassed initial enrollment targets, noted H.C. Wainwright analyst Vernon Bernardino. More >


Chris Temple

Expert Shares Thoughts on Six Stocks
Source: Chris Temple  (11/7/23)
Chris Temple of The National Investors shares a detailed report on stocks from the life science to the energy sector to tell you which he believes are Buys and which you should sell. More >


Biopharma Acquires Royalty on Approved Diabetes Drug
Source: Dr. Joseph Pantginis  (11/3/23)
This is one of the California-based company's many transactions resulting from its royalty monetization strategy, noted an H.C. Wainwright & Co. report. More >


Survey Results Positive for New HAE Drug
Source: Hartaj Singh  (11/2/23)
Most responding physicians, all with hereditary angioedema patients, indicated an "above average" impression of the treatment's safety and efficacy data, noted an Oppenheimer report. More >


Safety Profile of New IL-2 Molecule Better Than Like Drugs'
Source: Andres Maldonado  (11/2/23)
First clinical data of this investigational interleukin-2 cytokine show it lacks the degree and rates of adverse events typically seen with treatments of this kind, noted an H.C. Wainwright & Co. report. More >


Firm To Present Trial Results Update at SITC Meeting
Source: Dr. David Nierengarten  (11/2/23)
Data will be reviewed from Part B, the dose expansion portion, of the Phase 1 study of a new TGF-β1 isoform inhibitor in advanced cancer, noted a Wedbush report. More >


Chris Temple

Add Back Positions in This Biotech
Source: Chris Temple  (11/1/23)
Chris Temple of The National Investor shares one stock he believes is currently a Buy, as a gross overreaction caused sell-offs. More >


Biotech to Advance New Type 1 Diabetes Drug Into Clinic
Source: Edward White  (10/23/23)
Dosing of the first patient is expected in Q4/23 in this Phase 1 trial to be done in Australia, noted an H.C. Wainwright & Co. report. More >


Showing Results: 26 to 50 of 1874 Prev Next

Notable Quotes

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts